Drugs / PF-00489791
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02319148 | Jul → Oct 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 25 trials · 2 met primary · 3 missed | ||||||
| Phase 2 | NCT01200394 | Dec 2010 → Jul 2013 | diabetic kidney disease | Pfizer | Completed | Missed primary |
| Phase 2 | NCT01090492 | Aug 2010 → May 2011 | Raynaud disease | Pfizer | Completed | Met primary |
| Phase 2 | NCT00853112 | Apr 2009 → Jul 2010 | pulmonary arterial hypertension | Pfizer | Terminated | Missed primary |
| Phase 2 | NCT00599638 | Apr → Dec 2008 | postherpetic neuralgia | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00422461 | Feb 2007 → Jan 2008 | essential hypertension | Pfizer | Completed | Met primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PF-00489791 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01200394 ↗ |
| Known as | PF-489,791 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4210847 ↗ |
| Known as | UK-489,791 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4210847 ↗ |
| Action | Inhibit | “inhibitor of phosphodiesterase type 5” NCT01200394 ↗1“Phosphodiesterase 5A inhibitor” CHEMBL4210847 ↗ |
| Modality | Small molecule | “a phosphodiesterase inhibitor” NCT01090492 ↗ |
| Route | Oral | “PF-00489791 20 mg titrated to 40 mg, oral, tablets, once daily, for 28 days” NCT00422461 ↗ |
| Target | PDE5A | “Phosphodiesterase 5A inhibitor” CHEMBL4210847 ↗ |